Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results

      -- 4Q 2013 net loss of $1.8 million, or $0.05 per share --


      News provided by

      Omeros Corporation

      Mar 13, 2014, 04:16 ET

      Share this article

      Share this article


      SEATTLE, March 13, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and financial results for the fourth quarter and year ended December 31, 2013, which include:

      • 4Q 2013 net loss of $1.8 million, or $0.05 per share, and for the full year of 2013 a net loss of $39.8 million, or $1.39 per share
      • Operating expenses in 4Q 2013 were $14.1 million including $2.4 million of non-cash expenses, and for the full year of 2013 were $52.1 million including non-cash expenses of $9.7 million
      • U.S. and European regulators accepted Omidria™ (OMS302) marketing applications for review
      • Omeros' OMS721 received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for complement-mediated thrombotic microangiopathies (TMAs)
      • Closed senior loan facility with Oxford Finance and MidCap Financial in March 2014, receiving $12.6 million in net proceeds
      • Received $12.5 million in settlement of insurance coverage lawsuit with former insurer

      "Omeros achieved a number of significant milestones in 2013," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "In addition to submitting the NDA and MAA for Omidria, we completed successful clinical trials for OMS824 and OMS721, advancing both into Phase 2 clinical programs. In connection with the latter two programs, OMS824 received Orphan Drug and Fast Track Designations for Huntington's disease and OMS721 received Orphan Drug Designation for complement-mediated thrombotic microangiopathies. 2014 promises to be an exciting year – we look forward to the planned commercial launch of Omidria, Phase 2 data in Huntington's disease and TMAs, and continued success across our pipeline."

      Fourth Quarter and Recent Highlights

      • U.S. and European regulators accepted Omidria marketing applications for review. Omeros is preparing for a planned commercial launch of Omidria in the second half of 2014.
      • Received Orphan Drug designation for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), for the treatment of complement-mediated TMAs.
      • Closed a senior credit facility with Oxford Finance and MidCap Financial in March 2014, consisting of a $32.0 million term loan. The new loan requires interest-only payments through March 2015 and thereafter calls for monthly principal and interest payments through March 2018. Omeros used a portion of the loan proceeds to repay its obligations under its prior loan and security agreement with Oxford Finance and affiliates, and the remaining net proceeds of approximately $12.6 million will be used for general corporate purposes and working capital.
      • Began enrollment in the first quarter of 2014 in a Phase 2 clinical trial evaluating OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in patients with Huntington's disease. OMS824 also received Fast Track Designation from the FDA for the treatment of cognitive impairment in patients with Huntington's disease.
      • Announced positive results from its OMS824 Phase 2a clinical trial, in which OMS824 was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with stable schizophrenia, opening the potential for OMS824 to be delivered as monotherapy or as an adjunct to commercially available antipsychotics.
      • Reported positive data following completion of dosing in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). Omeros expects to initiate a Phase 2 clinical trial to evaluate OMS721 in the treatment of TMAs in the second quarter of 2014.
      • Received positive data using OMS721 in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of TMA. The data reported showed that OMS721 significantly inhibited complement deposition in the system using serum samples from aHUS patients obtained during the acute phase of disease (p<0.01) and during remission (p<0.001) compared to untreated controls.
      • Announced that it had identified compounds that functionally interact with each of six additional orphan G protein-coupled receptors (GPCRs), bringing the number of Class A orphan GPCRs reported "unlocked" by Omeros to 52. Omeros also reported that it had identified small molecules that interact with two non-orphan Class B GPCRs, the glucagon-like peptide 1 receptor (GLP-1R) and the parathyroid hormone 1 receptor (PTH-1R).
      • Entered into a settlement agreement with Carolina Casualty Insurance Company, or, CCIC, in October 2013, related to CCIC's defense of, and coverage obligations owed to, Omeros and its chief executive officer and chairman, Dr. Demopulos, in previously settled litigation. The settlement included a release of each party's respective claims in the insurance coverage lawsuit and payment by CCIC of $12.5 million to Omeros.

      Financial Results
      Operating expenses for the three months ended December 31, 2013 were $14.1 million, including $2.4 million of non-cash expenses, compared to $9.1 million, including $2.6 million of non-cash expenses, for the same period in 2012. During the fourth quarter of 2012, operating expenses were reduced by $3.95 million due to a reimbursement Omeros received from its former insurer for expenses Omeros recognized in the third quarter of 2012 in connection with a litigation settlement. Excluding this reimbursement, Omeros' operating expenses for the three months ended December 31, 2013 increased by $1.0 million from the prior year period. The increase was primarily related to our Phase 1 clinical trials evaluating OMS824 and OMS721, legal costs for patents, employee costs and expenses associated with preparing for our planned commercial launch of Omidria in the U.S. These increased expenses were partially offset by lower clinical research and development expenses in the three months ended December 31, 2013 as compared to the same period in 2012 due to completion of our Omidria Phase 3 clinical trial in January 2013 and the completion of the first OMS103 Phase 3 clinical trial for meniscectomy in December 2012.

      Operating expenses for the year ended December 31, 2013 were $52.1 million, including $9.7 million of non-cash expenses, compared to $42.9 million, including $4.9 million of non-cash expenses, in 2012. The 2013 increase related primarily to our Phase 1 clinical trials evaluating OMS824 and OMS721, non-cash rent expense associated with the lease of our new facilities, higher expenses related to the preparation and filing of the NDA and MAA and planned commercial launch for Omidria and increased legal and employee costs, including non-cash stock-based compensation.  These increased expenses were partially offset by lower clinical research and development expenses related to the completion of our Omidria Phase 3 clinical trial in January 2013 and the first OMS103 Phase 3 clinical trial for meniscectomy in December 2012. These two clinical programs were ongoing during 2012.

      Revenue for the year ended December 31, 2013, was $1.6 million, compared to $6.0 million in 2012.  The decrease was primarily due to lower deferred revenue being recognized from our GPCR funding agreements, which were fully amortized in the first quarter of 2013. 

      For the quarter ended December 31, 2013, Omeros reported a net loss of $1.8 million, or $0.05 per share. The receipt of $12.5 million in October 2013 from Omeros' settlement with CCIC reduced our net loss by $0.41 per share. This compares to a net loss of $7.7 million, or $0.30 per share, for the same period in 2012, including a $3.95 million ($0.15 per share) reduction of our loss related to a payment received upon settlement of litigation. Noncash expenses were $2.4 million ($0.08 per share) for the quarter ended December 31, 2013 and $2.6 million ($0.10 per share) for the same period in 2012.

      For the year ended December 31, 2013, Omeros reported a net loss of $39.8 million, or $1.39 per share. The receipt of the $12.5 million settlement payment from CCIC reduced our net loss by $0.44 per share. This compares to a net loss of $38.4 million, or $1.59 per share, in 2012. Noncash expenses were $9.7 million ($0.34 per share) for 2013 and $4.9 million ($0.20 per share) for 2012.

      At December 31, 2013, Omeros had cash and cash equivalents and short-term investments of $14.1 million.

      About Omeros Corporation
      Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the company's lead drug product, Omidria (OMS302) for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with U.S. commercial launch planned for the second half of 2014. Omeros' six other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

      Forward-Looking Statements
      This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros' unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims, competitive developments and the risks, uncertainties and other factors described under the heading "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements unless required by law, even if new information becomes available in the future.

      OMEROS CORPORATION

      CONSOLIDATED STATEMENTS OF OPERATIONS

      (In thousands, except share and per share data)
























      Three Months Ended


      Twelve Months Ended



      December 31,


      December 31,



      2013


      2012


      2013


      2012



      (unaudited)





      Revenue


      $             169


      $         1,583


      $              1,600


      $              6,022

      Operating expenses:









      Research and development


      10,186


      9,354


      36,297


      31,922

      General and administrative


      3,885


      3,715


      15,819


      10,985

      Litigation settlement


      -


      -


      -


      3,953

      Litigation recovery


      -


      (3,953)


      -


      (3,953)

      Total operating expenses


      14,071


      9,116


      52,116


      42,907

      Loss from operations


      (13,902)


      (7,533)


      (50,516)


      (36,885)

      Litigation settlement


      12,500


      -


      12,500


      -

      Investment income


      2


      8


      12


      40

      Interest expense


      (598)


      (369)


      (2,366)


      (1,729)

      Other income (expense), net


      153


      160


      574


      130

      Net loss


      $       (1,845)


      $       (7,734)


      $         (39,796)


      $         (38,444)

      Basic and diluted net loss per share


      $         (0.05)


      $         (0.30)


      $              (1.39)


      $              (1.59)

      Weighted-average shares used to compute basic and diluted net loss per share










      30,289,041


      25,886,586


      28,560,360


      24,155,690

      OMEROS CORPORATION

      CONSOLIDATED BALANCE SHEET DATA

      (In thousands)



      December 31,


      December 31,



      2013


      2012











      Cash and cash equivalents and short-term investments


      $            14,101


      $            22,350

      Total assets


      16,535


      26,575

      Total notes payable


      20,498


      20,103

      Total current liabilities


      11,873


      8,359

      Accumulated deficit


      (254,373)


      (214,577)

      Total shareholders' (deficit) equity


      (18,384)


      (6,531)

      SOURCE Omeros Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.